שווי מתואם לחוב ומזומנים biolinerx.com (BLRX)

The price history of BioLineRx Ltd. (BLRX) reflects the valuation dynamics of the company, which currently stands at 7.72. The Israeli business relies on Aphexda sales in the US and partnership contracts to drive cash flow growth. Success in treating myeloma has secured physician trust and market resilience for the brand. High margins and patent protection for approved treatments guarantee long-term development.

Patent protection for the BioLineRx Ltd. (BLRX) stem cell mobilization platform creates a high barrier to entry for competitors in oncology. The capitalization of these intangible assets, adjusted for net debt, forms the final enterprise value. This metric determines the actual cost of a full business buyout, accounting for liabilities. It allows for the identification of asset overvaluation during periods of speculative growth. Analyzing the core business value helps investors assess the adequacy of the market price.